Insights & Resources

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

A recent U.S. complaint highlights the growing need for health care systems to ensure physician compensation aligns with fair market value to avoid compliance risks.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.

The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.

California issued new financial statement requirements that are effective as of January of last year for skilled nursing facilities (SNF).

Managing revenue cycles is an important aspect of modern hospital operations. Defined business processes and strong internal controls are the keys to optimization.

The home health and hospice sectors are facing significant challenges with personal care emerging as the key sector for mitigating risk.

High-growth specialties are influencing the fair market value of ambulatory surgery centers and setting new standards for premium valuations.

Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.

Change Healthcare was impacted by a cybersecurity incident that breached its information technology network.